title: Physicians' attitudes and practice toward treating injection drug users with hepatitis C: results from a national specialist survey in Canada.
abstract: BACKGROUND
  In Canada, more than 70% of new cases of hepatitis C virus (HCV) infection per year involve injection drug users (IDUs) and, currently, there is no consensus on how to offer them medical care.
  
  
  OBJECTIVE
  To examine the characteristics of Canadian specialist physicians and their likelihood to provide treatment to HCV patients who are IDUs.
  
  
  METHODS
  A nationwide, cross-sectional study was conducted in the specialty areas of hepatology, gastroenterology and infectious diseases to examine HCV services. The questionnaire requested information regarding basic demographics, referral pathways and opinions (yes⁄no), and examined how a physician's treatment regimen is influenced by factors such as treatment eligibility, HCV care management and barriers to providing quality service.
  
  
  RESULTS
  Despite the fact that the majority of prevalent and incident cases of HCV are associated with injection drug use, very few specialist physicians actually provide the necessary therapy to this population. Only 19 (19.79%) comprehensive service providers were likely to provide treatment to a current IDU who uses a needle exchange on a regular basis. The majority of comprehensive service providers (n=86 [89.58%]) were likely to provide treatment to a former IDU who was stable on substitution therapy. On bivariate analysis, factors associated with the likelihood to provide treatment to current IDUs included physicians' type, ie, infectious disease specialists compared with noninfectious specialists (OR 3.27 [95% CI 1.11 to 9.63]), and the size of the community where they practice (OR 4.16 [95% CI 1.36 to 12.71] [population 500,000 or greater versus less than 500,000]). Results of the multivariate logistic regression analysis were largely consistent with the results observed in the bivariate analyses. After controlling for other confounding variables, only community size was significantly associated with providing treatment to current IDUs (OR 3.89 [95% CI 1.06 to 14.26] [population 500,000 or greater versus less than 500,000]).
  
  
  CONCLUSIONS
  The present study highlighted the reluctance of specialists to provide treatment to current IDUs infected with HCV. Providing treatment services for HCV-infected substance abusers is challenging and there are many treatment barriers. However, effective delivery of treatment to this population will help to limit the spread of HCV. The present study clearly identified a need for improved HCV treatment accessibility for IDUs.
authors.affiliation: Division of Community Health and Humanities, Memorial University of Newfoundland.
authors.forename: Angelique
authors.initials: A
authors.lastname: Myles
authors.forename: Gerry J
authors.initials: GJ
authors.lastname: Mugford
authors.forename: Jing
authors.initials: J
authors.lastname: Zhao
authors.forename: Murray
authors.initials: M
authors.lastname: Krahn
authors.forename: Peizhong P
authors.initials: PP
authors.lastname: Wang
mesh_terms: D000328:Adult; D001291:Attitude of Health Personnel; D002170:Canada / Q000453:epidemiology; D002983:Clinical Competence / Q000592:standards*; D003144:Communication Barriers; D003191:Comprehensive Health Care / Q000458:organization & administration; D003430:Cross-Sectional Studies; D004608:Eligibility Determination / Q000592:standards; D005260:Female; D006297:Health Services Accessibility; D006526:Hepatitis C / Q000209:etiology / Q000628:therapy; D006801:Humans; D033183:Interdisciplinary Communication; D008297:Male; D008875:Middle Aged; D010820:Physicians / Q000523:psychology / Q000592:standards; D017751:Safety Management / Q000458:organization & administration*; D015819:Substance Abuse, Intravenous / Q000150:complications / Q000453:epidemiology; D011795:Surveys and Questionnaires